Clinical trials
Breast Cancer Screening and Diagnosis clinical trials
Below are recruiting breast cancer screening and diagnosis clinical trials, each written for real people, not researchers. We’re tracking 255 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04030507Recruiting
Brain MRI screening during chemotherapy for breast cancer
This trial checks the brain using MRI in people with breast cancer that has spread outside the breast or can’t be fully removed. The goal is to screen for brain involvement and see how MRI findings fit with treatment timing, when it’s safe to do so.
Boston, MassachusettsAges 18 years+ - NCT04038619RecruitingPhase 1
Fecal transplant for immune-therapy diarrhea or bowel inflammation
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Houston, TexasAges 18 years+ - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT04362826Recruiting
Trial tests a probiotic to change gut microbes in breast cancer
This study gives a probiotic to see whether it safely changes the gut’s bacteria and fungi (your “microbiome”) in people with breast cancer. The researchers want to learn if this shift in gut microbes might support breast cancer treatment or health during care.
Cleveland, OhioAges 18–65 - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT04523857RecruitingPhase 2
Abemaciclib and hydroxychloroquine after breast cancer relapse risk
This Phase 2 trial tests whether abemaciclib plus hydroxychloroquine can kill tiny “leftover” cancer cells in the bone marrow after standard breast cancer treatment. It may help lower the chance of cancer coming back by targeting minimal residual disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04590560Recruiting
Best timing for breast screening in women ages 45–49 and 70–74
This study looks at the best time interval for breast cancer screening (mammograms) for women in two age groups. The goal is to reduce missed cancers while avoiding unnecessary tests.
Meldola (FC), FCAges 45–49 - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05115474RecruitingPhase 2
Screening brain MRI study for stage IV breast cancer
This trial checks whether taking screening brain MRI scans in people with stage IV breast cancer helps find brain involvement earlier. It may help guide treatment decisions for those who would otherwise only get brain imaging after symptoms start.
Clearwater, FloridaAges 18 years+ - NCT05386719Recruiting
Cardiometabolic screening for people after early breast cancer
This trial tests a screening program to look for heart- and metabolism-related health risks in people who have completed treatment for early breast cancer. It may help catch problems earlier so you can get timely care.
Baltimore, MarylandAges 18 years+ - NCT05455619RecruitingPhase 1/Phase 2
Targeted drugs for PI3K-altered, HR+/HER2- breast cancer
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
Loma Linda, CaliforniaAges 18 years+ - NCT05465031RecruitingPhase 4
Testing heart-protection medicine during breast cancer treatment
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
Opole, Opole VoivodeshipAges 18 years+ - NCT05468034Recruiting
Exercise program for metastatic breast cancer using a phone
This trial studies how a supervised exercise program (with treadmill walking and phone tracking) affects people living with metastatic breast cancer. It may help by improving fitness and day-to-day ability, especially if you’re currently not meeting regular exercise goals.
New Haven, ConnecticutAges 18 years+ - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05491226RecruitingPhase 2
Pembrolizumab plus radiation and myeloid-targeting for high-risk breast cancer
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
Los Angeles, CaliforniaAges 18 years+ - NCT05504707RecruitingPhase 1
Study drug for early-stage, HER2-negative, low-risk hormone breast cancer
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
Tampa, FloridaAges 18 years+ - NCT05524584RecruitingPhase 2
Anastrozole, fulvestrant, and abemaciclib for hormone-positive breast cancer
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Orange, CaliforniaAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+
Hear when a new Breast Cancer Screening and Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening and diagnosis?
- Yes. Clin2 currently lists 255 recruiting breast cancer screening and diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening and diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening and diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.